Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives
This study (n=48) found that there is significant overlap in the neural correlates of classic serotonergic psychedelics (psilocybin, LSD) and ketamine, even though the mechanism of action is not the same.
Authors
- Suresh Muthukumaraswamy
- Enzo Tagliazucchi
- Robin Carhart-Harris
Published
Abstract
Classic serotonergic psychedelics are remarkable for their capacity to induce reversible alterations in consciousness of the self and the surroundings, mediated by agonism at serotonin 5-HT2A receptors. The subjective effects elicited by dissociative drugs acting as N-methyl-D-aspartate (NMDA) antagonists (e.g. ketamine and phencyclidine) overlap in certain domains with those of serotonergic psychedelics, suggesting some potential similarities in the brain activity patterns induced by both classes of drugs, despite different pharmacological mechanisms of action. We investigated source-localized magnetoencephalography recordings to determine the frequency-specific changes in oscillatory activity and long-range functional coupling that are common to two serotonergic compounds (lysergic acid diethylamide [LSD] and psilocybin) and the NMDA-antagonist ketamine. Administration of the three drugs resulted in widespread and broadband spectral power reductions. We established their similarity by using different pairs of compounds to train and subsequently evaluate multivariate machine learning classifiers. After applying the same methodology to functional connectivity values, we observed a pattern of occipital, parietal and frontal decreases in the low alpha and theta bands that were specific to LSD and psilocybin, as well as decreases in the low beta band common to the three drugs. Our results represent a first effort in the direction of quantifying the similarity of large-scale brain activity patterns induced by drugs of different mechanism of action, confirming the link between changes in theta and alpha oscillations and 5-HT2A agonism, while also revealing the decoupling of activity in the beta band as an effect shared between NMDA antagonists and 5-HT2A agonists. We discuss how these frequency-specific convergences and divergences in the power and functional connectivity of brain oscillations might relate to the overlapping subjective effects of serotonergic psychedelics and glutamatergic dissociative compounds.
Research Summary of 'Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives'
Introduction
Pallavicini and colleagues situate their work within a long-standing distinction between serotonergic psychedelics (SP) and glutamatergic dissociatives (GD), noting that both classes produce marked alterations of perception and self-experience yet have distinct primary molecular targets (5-HT2A receptor agonism for SP; NMDA receptor antagonism for GD). Earlier neuroimaging and pharmacological studies show overlapping system-level effects (for example, altered default mode network activity, reductions in lower-frequency oscillatory power and increased global connectivity/entropy), but there has been no quantitative, frequency-specific comparison of the acute neurophysiological signatures induced by representative compounds from the two classes. The study set out to compare MEG-derived, source-localised spectral power and long-range functional connectivity changes produced acutely by two serotonergic psychedelics (LSD and psilocybin) and one NMDA-antagonist dissociative (ketamine). The investigators aimed to: (1) identify band-limited power and connectivity changes for each drug versus placebo; (2) quantify the spatial similarity of those changes between drugs; and (3) test whether multivariate classifiers trained to distinguish a given drug from its placebo generalise to distinguish other drugs from their placebos. The approach emphasises frequency-specific patterns as potential convergent or divergent neurophysiological signatures tied to pharmacology and subjective effects.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typeindividual
- Journal
- Compounds
- Topic
- Authors
- APA Citation
Pallavicini, C., Vilas, M. G., Villarreal, M., Zamberlan, F., Muthukumaraswamy, S., Nutt, D., Carhart-Harris, R., & Tagliazucchi, E. (2019). Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives. NeuroImage, 200, 281-291. https://doi.org/10.1016/j.neuroimage.2019.06.053
References (33)
Papers cited by this study that are also in Blossom
Barrett, F. S., Preller, K. H., Herdener, M. et al. · Cerebral Cortex (2017)
Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)
Carhart-Harris, R. L., Leech, R., Erritzoe, D. et al. · Schizophrenia Bulletin (2012)
Carhart-Harris, R. L., Leech, R., Shanahan, M. et al. · Frontiers in Human Neuroscience (2014)
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)
Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · Neuroscience and Biobehavioral Reviews (2016)
Gonza ´lez-Maeso, J., Weisstaub, N. V., Zhou, M. et al. · Neuron (2007)
Halberstadt, A. L. · Behavioural Brain Research (2014)
Hanks, J. B., González-Maeso, J. · ACS Chemical Neuroscience (2012)
Kometer, M., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Show all 33 referencesShow fewer
Kometer, M., Pokorny, T., Seifritz, E. et al. · Psychopharmacology (2015)
Sumiyoshi, T., Kraehenmann, R., Pokorny, D. et al. · Frontiers in Pharmacology (2017)
Kraehenmann, R. ;., Pokorny, D. ;., Vollenweider, L. ;. et al. · Psychopharmacology (2017)
Lebedev, A. V., L€ Ovd En, M., Rosenthal, G. et al. · Human Brain Mapping (2015)
Lebedev, A. V., Kaelen, M., L€ Ovd En, M. et al. · Human Brain Mapping (2016)
Millière, R. · Frontiers in Human Neuroscience (2017)
Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R. J. et al. · Journal of Neuroscience (2013)
Nichols, D. E. · Pharmacology and Therapeutics (2004)
Palhano-Fontes, F., Andrade, K. C., Tófoli, L.F. et al. · PLOS ONE (2015)
Preller, K. H., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Preller, K. H., Herdener, M., Pokorny, T. et al. · Current Biology (2017)
Preller, K. H., Burt, J. B., Adkinson, B. et al. · eLife (2018)
Ray, T. S. · PLOS ONE (2010)
Riba, J., Anderer, P., Morte, A. et al. · British Journal of Clinical Pharmacology (2002)
Riba, J., Anderer, P., Jané, F. et al. · Neuropsychobiology (2004)
Rickli, A., Luethi, D., Reinisch, J. et al. · Neuropharmacology (2015)
Rickli, A., Moning, O. D., Hoener, M. C. et al. · European Neuropsychopharmacology (2016)
Roseman, L., Leech, R., Feilding, A. et al. · Frontiers in Human Neuroscience (2014)
Schartner, M., Carhart-Harris, R. L., Barrett, A. B. et al. · Scientific Reports (2017)
Tagliazucchi, E., Roseman, L., Kaelen, M. et al. · Current Biology (2016)
Vollenweider, F. X., Kometer, M. · Nature Reviews Neuroscience (2010)
Wacker, D., Wang, S., Mccorvy, J. D. et al. · Cell (2017)
Zamberlan, F., Sanz, C., Pallavicini, C. et al. · Frontiers in Integrative Neuroscience (2018)
Cited By (14)
Papers in Blossom that reference this study
Lewis-Healey, E., Pallavicini, C., Cavanna, F. et al. · Journal of Cognitive Neuroscience (2025)
Silva-Costa, N., Pessoa, J. A., Andrade, K. C. et al. · Journal of Psychopharmacology (2025)
Blackburne, G., Mcalpine, R. G., Fabus, M. et al. · Cell Reports (2025)
Shinozuka, K., Tewarie, P. K. B., Luppi, A. et al. · Biorxiv (2024)
Li, D., Vlisides, P. E., Mashour, G. A. · NeuroImage (2022)
Elman, I., Borsook, D., Pustilink, A. · Neuroscience and Biobehavioral Reviews (2022)
Vejmola, Č., Tylš, F., Piorecká, V. et al. · Translational Psychiatry (2021)
Pasquini, L., Luke, D., Harris, R. E. et al. · Frontiers in Human Neuroscience (2021)
González, J., Cavelli, M., Castro-Zaballa, S. et al. · ACS Pharmacology and Translational Science (2021)
Hibicke, M., Gobbi, G. · Journal of Neuroscience (2020)
Show all 14 papersShow fewer
Kadriu, B., Greenwald, M., Ba et al. · International Journal of Neuropsychopharmacology (2020)
Vollenweider, F. X., Preller, K. H. · Nature Reviews Neuroscience (2020)
Girn, M., Roseman, L., Bernhardt, B. et al. · Biorxiv (2020)
Barnett, L., Muthukumaraswamy, S., Carhart-Harris, R. L. · NeuroImage (2020)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.